Biotech

All Articles

Lilly posts extra good data on its once a week insulin possibility

.On the heels of an FDA rejection for its own primary rivalrous Novo Nordisk, Eli Lilly is actually ...

IN 8bio stops phase 2 test, lays off half of labor force

.Simply a couple of months after application the very first person in a period 2 test for recently d...

Lilly, Haya ink $1B biobuck excessive weight contract to look black genome

.Eli Lilly's look for being overweight targets has led it to the dark genome. The Big Pharma has cre...

ArsenalBio raises $325M, rotates off of former lead resource

.Collection Biosciences is carrying on up. The tissue therapy provider has added $325 million in amm...

Lilly- backed weight-loss biotech reports IPO

.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has submitte...

Aelis' cannabis make use of drug fails phase 2b, driving Indivior to re-think $100M choice

.Aelis Farma's hopes of safeguarding a quick, favorable choice on a $100 million choice payment have...

ProKidney stops period 3 test certainly not required for tissue therapy authorization

.ProKidney has actually quit among a set of phase 3 tests for its tissue therapy for renal condition...

Vaxcyte climbs on 'sensational' 31-valent PCV gain against Pfizer

.Vaxcyte unveiled what experts named "magnificent" stage 1/2 data for its own 31-valent pneumococcal...

Recursion's human brain disease trial reveals scant documentation of efficacy

.Recursion has stumbled with an early examination of its own tech-enabled approach to drug discovery...

Acepodia, Pfizer click on with each other for chemistry-based cell therapy

.Call it a case of good chemical make up: Acepodia, a biotech based upon Nobel Champion scientific r...